Log in

BTCY BIOTRICITY INC. OTC · United States

BIOTRICITY INC. (BTCY) news

BIOTRICITY INC. is a public biotech or pharmaceutical company listed on OTC under the ticker BTCY, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest BIOTRICITY INC. news

We have not published a story on BIOTRICITY INC. yet. When there is news, it will appear here.

What BIOTRICITY INC. does

Biotricity Inc. is a medical technology company focused on biometric data monitoring, offering remote monitoring solutions to the medical, healthcare and consumer markets. It first focused on mobile cardiac outpatient monitoring with its Bioflux device and software, which has FDA clearance. Its flagship technology is the Biocore Pro, the cellular version of its three-lead Biocore device for ECG and arrhythmia monitoring, which is intended for lower risk patients. The company also offers Bioheart, a direct-to-consumer heart monitor. It says it has expanded its sales efforts to 35 states and intends to compete more broadly in the US market using an insourcing model, in which physicians use its technology and the company earns utilization-based technology service fees. The company has obtained regulatory approvals in several jurisdictions outside the US. It plans to expand into remote patient monitoring, chronic care management and implantable device management, with a goal of becoming an all-in-one cardiac diagnostic and disease management solution. Target customers include hospitals, clinics, physicians' offices and independent diagnostic testing facilities.

Product or programWhat it isStage
BiofluxMobile cardiac outpatient monitoring device and softwareFDA cleared
Biocore ProCellular three-lead ECG and arrhythmia monitoring device, flagship technologylaunched
BiocoreThree-lead connected Holter monitoring patch for lower risk patientsFDA cleared
BioheartDirect-to-consumer heart monitorlaunched

Summarised from the company's 10-K filed Jul 14, 2026.

BIOTRICITY INC. annual financials

LineFY ended Mar 31, 2026FY ended Mar 31, 2025
Research and development$2.8 million$2.2 million
Net income (loss)-$2.4 million-$8.4 million
Cash from operations-$718,955-$2.4 million
Cash and equivalents$149,789$365,145

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $466,503.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about BIOTRICITY INC.

What is the ticker symbol of BIOTRICITY INC.?

BIOTRICITY INC. trades under the ticker BTCY on OTC.

Where is BIOTRICITY INC. listed?

BIOTRICITY INC. is listed on OTC.

Which country or territory is BIOTRICITY INC. listed under?

Our directory records BIOTRICITY INC. under United States.

Does aibio.space cover BIOTRICITY INC.?

aibio.space lists BIOTRICITY INC. among 2,820 public biotech companies and publishes its news here as stories appear.

What does BIOTRICITY INC. develop?

Biotricity Inc. is a medical technology company focused on biometric data monitoring, offering remote monitoring solutions to the medical, healthcare and consumer markets. It first focused on mobile cardiac outpatient monitoring with its Bioflux device and software, which has FDA clearance.

What is Bioflux from BIOTRICITY INC.?

Bioflux: Mobile cardiac outpatient monitoring device and software Stage: FDA cleared.

What is Biocore Pro from BIOTRICITY INC.?

Biocore Pro: Cellular three-lead ECG and arrhythmia monitoring device, flagship technology Stage: launched.

Is BIOTRICITY INC. profitable?

BIOTRICITY INC. reported a net loss of $2.4 million for the fiscal year ended Mar 31, 2026, and used $718,955 of cash in operations, per its annual report to the SEC.

How much does BIOTRICITY INC. spend on research and development?

$2.8 million in the fiscal year ended Mar 31, 2026, per its annual report.

How much cash does BIOTRICITY INC. have?

$466,503 in cash at Jun 30, 2026, per its 10-Q.

Investor discussion: BIOTRICITY INC.

Members talk about BIOTRICITY INC. (BTCY). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at BIOTRICITY INC., newest first. Each line links the filing it comes from.

  1. Distress

    Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source

  2. Distress

    Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source

  3. Financings

    Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,9.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:BTCY on TradingView.

Listing details

BIOTRICITY INC. is a public biotech or pharmaceutical company listed on OTC under the ticker BTCY, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
BIOTRICITY INC.
Ticker
BTCY
Listing
OTC
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.